AYTU

MKT CAP:$21M

Aytu BioPharma, Inc.

Market Cap

$21M

Healthcare·Drug Manufacturers - Specialty & Generic·🇺🇸 United States·NASDAQ

Healthcare·Drug·🇺🇸·NASDAQ

Stock Price

$2.58-$0.19 (-6.86%)

Apr 23, 2026

Company Details

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatme...

CEO

Joshua R. Disbrow

IPO Date

Sep 25, 2008

Website

aytubio.com

Key Metrics TTM

Revenue

$63M

-3.3% YoY

Net Income

-$24M

EPS (Diluted)

-$3.84

Free Cash Flow

-$698.0K

Revenue / Share

$6.24

Gross Margin

66.0%

Operating Margin

-13.9%

Net Margin

-39.0%

FCF Margin

-1.1%

P/S

0.3x

P/E

—

Earnings Reports

Q3 2026

May 13, 2026

PENDING

Q2 2026

Feb 3, 2026

$15M-6.5%EPS -$1.05

Q1 2026

Nov 13, 2025

$14M-16.2%EPS -$0.08

FY 2025

Sep 23, 2025

$66M+1.8%EPS -$2.16

Q4 2025

Sep 23, 2025

$15M-15.8%EPS -$2.92

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q3 22	$24M	$13M	-$53M
Q4 22	$27M	$13M	-$17M
Q1 23	$28M	$18M	-$2M
Q2 23	$26M	$17M	-$7M
Q3 23	$23M	$13M	-$9M
Q4 23	$31M	$19M	$169.0K
Q1 24	$18M	$13M	-$867.0K
Q2 24	$19M	$15M	$3M
Q3 24	$14M	$10M	-$2M
Q4 24	$18M	$12M	-$4M
Q1 25	$17M	$12M	-$930.0K
Q2 25	$16M	$11M	-$2M
Q3 25	$18M	$13M	$2M
Q4 25	$15M	$10M	-$8M
Q1 26	$14M	$9M	-$2M
Q2 26	$15M	$9M	-$2M

Valuation

Quarter	P/S	P/E
Q3 22	0.2x	—
Q4 22	0.2x	—
Q1 23	0.2x	—
Q2 23	0.2x	—
Q3 23	0.2x	—
Q4 23	0.2x	—
Q1 24	0.2x	—
Q2 24	0.2x	—
Q3 24	0.3x	—
Q4 24	0.3x	—
Q1 25	0.3x	—
Q2 25	0.3x	—
Q3 25	0.3x	12.6x
Q4 25	0.3x	—
Q1 26	0.3x	—
Q2 26	0.3x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q3 22	-$9M	-$9M
Q4 22	-$7M	-$7M
Q1 23	-$9M	-$9M
Q2 23	-$2M	-$2M
Q3 23	-$3M	-$3M
Q4 23	$9M	$9M
Q1 24	-$211.0K	-$211.0K
Q2 24	-$135.0K	-$135.0K
Q3 24	-$254.0K	-$254.0K
Q4 24	-$788.0K	-$1M
Q1 25	-$1M	-$1M
Q2 25	$3M	$3M
Q3 25	-$6M	-$7M
Q4 25	$3M	$3M
Q1 26	-$618.0K	-$618.0K
Q2 26	$4M	$4M

Capital Expenditures

Quarter	CapEx
Q3 22	$0
Q4 22	$0
Q1 23	$0
Q2 23	$0
Q3 23	$0
Q4 23	$0
Q1 24	$0
Q2 24	$0
Q3 24	$0
Q4 24	$329.0K
Q1 25	$136.0K
Q2 25	$6.0K
Q3 25	$69.0K
Q4 25	$17.0K
Q1 26	$0
Q2 26	$17.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q3 22	+79.5%	+98.3%
Q4 22	+16.9%	-6.7%
Q1 23	+26.3%	-40.6%
Q2 23	+13.6%	-3.7%
Q3 23	-6.1%	-59.7%
Q4 23	+12.0%	-31.1%
Q1 24	-35.6%	-36.6%
Q2 24	-28.7%	-52.9%
Q3 24	-38.3%	-50.1%
Q4 24	-41.5%	-29.2%
Q1 25	-7.0%	-6.3%
Q2 25	-13.5%	+14.8%
Q3 25	+31.6%	+2.6%
Q4 25	-15.8%	+5.2%
Q1 26	-16.2%	-12.1%
Q2 26	-6.5%	-4.4%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q3 22	$0	0.0%
Q4 22	$1M	4.5%
Q1 23	$1M	4.3%
Q2 23	$3M	11.7%
Q3 23	$902.0K	4.0%
Q4 23	$900.0K	2.9%
Q1 24	$725.0K	4.1%
Q2 24	$707.0K	3.8%
Q3 24	$699.0K	5.0%
Q4 24	$242.0K	1.3%
Q1 25	$173.0K	1.0%
Q2 25	$151.0K	0.9%
Q3 25	$139.0K	0.8%
Q4 25	$0	0.0%
Q1 26	$114.0K	0.8%
Q2 26	$283.0K	1.9%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q3 22	$3M	$8M	$10M
Q4 22	$3M	$7M	$10M
Q1 23	$1M	$7M	$10M
Q2 23	$2M	$8M	$11M
Q3 23	$856.0K	$7M	$13M
Q4 23	$465.0K	$6M	$8M
Q1 24	$595.0K	$6M	$6M
Q2 24	$521.0K	$5M	$5M
Q3 24	$611.0K	$5M	$5M
Q4 24	$1M	$5M	$6M
Q1 25	$426.0K	$5M	$6M
Q2 25	$522.0K	$4M	$5M
Q3 25	$162.0K	$4M	$5M
Q4 25	$216.0K	$4M	$5M
Q1 26	—	$5M	$5M
Q2 26	—	$5M	$6M

Revenue Segments

Quarter

Revenue by Geography

Quarter	U.S.	Non-US	United States
Q3 22	$24M	—	—
Q4 22	—	$250.0K	$27M
Q1 23	—	$179.0K	$27M

War Chest

Quarter	Cash	Short-term Investments	Total
Q3 22	$28M	$0	$28M
Q4 22	$19M	$0	$19M
Q1 23	$24M	$0	$24M
Q2 23	$20M	$0	$20M
Q3 23	$19M	$0	$19M
Q4 23	$23M	$0	$23M
Q1 24	$20M	$0	$20M
Q2 24	$20M	$0	$20M
Q3 24	$20M	$0	$20M
Q4 24	$20M	$0	$20M
Q1 25	$20M	$0	$20M
Q2 25	$20M	$0	$20M
Q3 25	$18M	$0	$18M
Q4 25	$31M	$0	$31M
Q1 26	$33M	$0	$33M
Q2 26	$30M	$0	$30M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q3 22	1M	+12.1%	+64.4%
Q4 22	2M	+21.6%	+52.5%
Q1 23	3M	+40.0%	+90.9%
Q2 23	3M	+23.4%	+135.6%
Q3 23	4M	+19.9%	+152.0%
Q4 23	4M	+8.8%	+125.6%
Q1 24	5M	+35.0%	+117.5%
Q2 24	6M	+0.7%	+77.4%
Q3 24	6M	+0.2%	+48.3%
Q4 24	6M	+0.1%	+36.4%
Q1 25	9M	+64.3%	+66.1%
Q2 25	8M	-6.8%	+53.8%
Q3 25	8M	-3.3%	+48.4%
Q4 25	7M	-17.2%	+22.6%
Q1 26	19M	+186.8%	+114.0%
Q2 26	10M	-48.5%	+18.3%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q3 22	$138.3K	175
Q4 22	$167.4K	164
Q1 23	$168.6K	164
Q2 23	$160.2K	164
Q3 23	$138.6K	164
Q4 23	$204.9K	150
Q1 24	$118.8K	150
Q2 24	$125.0K	150
Q3 24	$93.5K	150
Q4 24	$176.2K	102
Q1 25	$162.5K	102
Q2 25	$159.0K	102
Q3 25	$180.9K	102
Q4 25	$182.3K	83
Q1 26	$167.3K	83
Q2 26	$182.7K	83

Revenue / Employee